Curriculum
- 11 Sections
- 147 Lessons
- 16 Hours
- Module 1: Introduction to Epidemiology in Clinical Practice14
- 1.1Module Outline
- 1.21. Overview of Epidemiology and Its Relevance to Patient Care
- 1.31.1 What is Epidemiology and Clinical Epidemiology?
- 1.41.2 The Purpose of Clinical Epidemiology
- 1.51.3 Basic Principles of Epidemiology
- 1.62. Role of Epidemiological Methods in Improving Clinical Outcomes
- 1.72.1 Use of Epidemiological Findings to Guide Treatment Protocols and Public Health Policies
- 1.82.2 Evidence-Based Clinical Guidelines Derived from Epidemiological Research
- 1.92.3 Sensitivity, Specificity and Predictive Value in Diagnostic Tests
- 1.102.4 Role in Improving the Accuracy and Reliability of Clinical Diagnostics
- 1.112.5 Real-World Example: How Epidemiological Research Influenced Clinical Practice
- 1.123. Differentiating between clinical epidemiology and population epidemiology
- 1.133.1 Differences between clinical and population epidemiology
- 1.143.2 Interconnection Between Clinical and Population Epidemiology- How Population Epidemiology Informs Clinical Practice
- Module 2: Screening and Early Detection of Disease18
- 2.1Module Outline
- 2.21. Principles and Criteria for Effective Screening Programs
- 2.31.1 Definition of Screening Programs
- 2.41.2 Requirements for Instituting a Medical Screening Programme (Modern Criteria) and Revisiting the Wilson and Jungner Criteria
- 2.51.3 Types of Screening
- 2.61.4 Cost Effectiveness and Allocation in Screening
- 2.71.5 Over Diagnosis, Lead Time Bias, and Length Bias
- 2.81.6 Ethical Considerations in Screening
- 2.92. Use of Sensitivity, Specificity, Positive Predictive Value, and Negative Predictive Value in Evaluating Screening Tests
- 2.102.1 Biologic Variation of Human Population
- 2.112.2 Validity of Screening Tests
- 2.122.3 Measures of Validity in Screening Tests
- 2.132.4 Measures of Performance in Screening
- 2.142.5 Relationship Between Predictive Value and Disease Prevalence
- 2.152.6 Receiver Operating Characteristic (ROC) Curves and Area Under The Curve (AUC)
- 2.162.7 Trade-Offs Between Sensitivity and Specificity
- 2.172.8 Application of Bayes’ Theorem in Interpreting Screening Results
- 2.182.9 Case Studies of Successful Screening Initiatives
- Module 3: Application of Epidemiology in Clinical Practice13
- 3.1Module Outline
- 3.21. Application of Incidence & Prevalence in Clinical Settings
- 3.31.1 Introduction to Incidence & Prevalence in Public Health
- 3.41.2 Using Disease Data to Guide Screening & Prevention
- 3.52. The Role of Relative Risk, Odds Ratio, and Hazard Ratio for Clinical Decision-Making
- 3.62.1 Introduction to Risk Measures in Epidemiology
- 3.72.2 Understanding Relative Risk (Risk Ratio)
- 3.82.3 Understanding Odds Ratio (OR) – Concept & Interpretation
- 3.92.4 Understanding Hazard Ratio (HR) – Concept & Interpretation
- 3.103. Using Epidemiological Data to Assess Patient Prognosis & Treatment Options
- 3.113.1 Understanding Survival Analysis & Life Tables
- 3.123.2 How Survival Data Helps in Selecting the Best Treatment
- 3.133.3 How Bias Affects Survival Data & Clinical Decisions
- Module 4: Application of Study Designs in Patient Care13
- 4.1Module Outline
- 4.21. How Cohort, Case-Control, and Cross-Sectional Studies Inform Clinical Decisions
- 4.31.1. Features of Cohort Studies and Their Use in Risk-Factor Analysis
- 4.41.2. Case-Control Study Methodology – Selecting Controls and Analysing Odds
- 4.51.3. Cross-Sectional Studies for Prevalence Measurement and Healthcare Surveys
- 4.62. The Impact of Randomised Controlled Trials (RCTs) on Treatment Protocols
- 4.72.1. Designing and Conducting RCTs
- 4.82.2. Real-World Examples of RCTs Influencing Practice
- 4.92.3. Ethical Considerations in Conducting RCTs
- 4.103. Understanding Observational Studies and Their Relevance to Real-World Patient Care
- 4.113.1. Role of Observational Studies in Understanding Long-Term Outcomes
- 4.123.2. Common Biases and Their Mitigation
- 4.133.3. Examples of Observational Studies Leading to Policy Changes
- Module 5: Evidence-Based Medicine in Clinical Practice1
- Module 6: Surveillance Systems and Clinical Decision Making20
- 6.1Module Outline
- 6.21. Role of Disease Surveillance in Guiding Clinical Practice
- 6.31.1 Definition and Scope of Disease Surveillance
- 6.41.2 Importance of Early Detection and Response to Emerging Health Threats
- 6.51.3 Types of Surveillance
- 6.61.4 Integration of Surveillance Data in Clinical Workflow
- 6.71.5 Limitations and Challenges in Using Surveillance Data in Clinical Practice
- 6.82. Using Epidemiological Data from National & Global Health Surveillance Systems
- 6.92.1 Overview of Major Health Surveillance Systems
- 6.102.2 How Surveillance Data Informs Policies & Clinical Guidelines
- 6.112.3 Methods for Accessing & Interpreting Surveillance Reports
- 6.122.4 Role of Epidemiological Dashboards
- 6.132.5 Examples of Data-Driven Response
- 6.142.6 Global Challenges and Examples
- 6.153. Real-Time Application of Epidemiological Surveillance in Patient Care
- 6.163.1 Real-Time Disease Tracking Tools
- 6.173.2 Surveillance Informing Clinical Practice
- 6.183.3 Application of Predictive Analytics and Artificial Intelligence
- 6.193.4 Challenges of Using Real-Time Surveillance
- 6.203.5 Collaboration Between Public and Healthcare Systems for Rapid Response
- Module 7: Introduction to Epidemiology in Clinical Practice13
- 7.1Module Outline
- 7.21. Role of Epidemiology in Controlling Infectious Disease Outbreaks
- 7.31.1 Basics of Transmission Dynamics (Agent, Host, Environment)
- 7.41.2 Phases of Infectiousness: Incubation, Latent, Communicable, and Generation Time
- 7.51.3 Application in Outbreak Control (e.g., Cholera, Dengue, COVID-19)
- 7.62. Application of Epidemiological Models in Clinical Settings
- 7.72.1 R0: Impact on Outbreak Control and Clinical Workflows (e.g., Quarantine Duration)
- 7.82.2 Herd Immunity: Vaccine Coverage Thresholds (e.g., Measles, Polio)
- 7.92.3 Limitations of Models in Real-World Patient Care Settings
- 7.103. Case Management and Contact Tracing Strategies in Infectious Diseases
- 7.113.1 Isolation and Treatment Protocols for Infectious Diseases (e.g., TB, COVID-19)
- 7.123.2 Contact Tracing Principles: Incubation Periods, Communicability, and Prioritization
- 7.133.3 Challenges in High-Density Settings Like Hospitals and Slums
- Module 8: Epidemiology and Chronic Disease Management16
- 8.1Module Outline
- 8.21. Use of Epidemiological Data in Managing Chronic Conditions
- 8.31.1. Advanced Data Analytics in Chronic Disease Management
- 8.41.2 Geospatial Analysis for Chronic Disease Surveillance (Mapping disease hotspots to allocate healthcare resources)
- 8.51.3 Integration of Electronic Health Records (EHR) in Epidemiological Studies (Leveraging EHR data for real-time disease monitoring)
- 8.61.4 Assessing the impact of socioeconomic factors on disease prevalence
- 8.71.5 Policy and Legal Frameworks for Data Sharing in Chronic Disease Management
- 8.82. Long-term Follow-up and Surveillance in Chronic Disease Care
- 8.92.1 Strategies to Improve Patient Adherence and Engagement in Long-term Follow-up
- 8.102.2 Implementing telehealth and mobile health (mHealth) solutions in chronic diseases surveillance
- 8.112.3 Data Integration and Analysis for Long-term Surveillance
- 8.123. Impact of lifestyle interventions based on epidemiological research
- 8.133.1 Evidence based lifestyle modification programs
- 8.143.2 Epidemiological Studies Supporting the Effectiveness of Lifestyle Changes in Reducing Risk Factors
- 8.153.3 Long-term impacts of lifestyle interventions: Data from longitudinal studies showing benefits in managing chronic diseases
- 8.163.4 Insights from Epidemiological Research on Effective Behavioral Interventions
- Module 9: Health Outcomes and Patient-Centred Care1
- Module 10: Epidemiology in Public Health37
- 10.1Module Outline
- 10.21. Role of Epidemiology in Public Health Policy & Program Planning
- 10.31.1. Data Collection and Analysis for Policy Development
- 10.41.2. Role of Epidemiology in Setting Health Priorities
- 10.51.3. Evidence-Based Public Health Planning
- 10.61.4. Evaluating the Impact of Public Health Policies
- 10.71.5. Case Studies: Tobacco Control, Vaccination Policies
- 10.82. Epidemiology of Emerging & Re-emerging Diseases
- 10.92.1. Factors Driving the Emergence and Re-Emergence of Diseases
- 10.102.2. Global Health Surveillance Systems
- 10.112.3. Examples: Zika Virus, Ebola, Antimicrobial Resistance, COVID-19, SARS, MERS, HMPV
- 10.122.4. Role of One Health Approach
- 10.132.5. Strategies for Prevention and Control
- 10.143. Travel-Related Epidemiology for Infectious Diseases & Global Health Risks
- 10.153.1. Epidemiology and Travel-Related Infections (eg: Malaria, Dengue, COVID-19)
- 10.163.2. Vaccination Requirements for Travelers
- 10.173.3. Role of International Health Regulations (IHR)
- 10.183.4. Disease Mapping and Risk Assessment for Travelers
- 10.193.5. Public Health Advisories and Travel Bans
- 10.204. Monitoring NCD Trends & Interventions
- 10.214.1. Epidemiology of Key NCDs (Diabetes, Cardiovascular Diseases, Cancers, etc.)
- 10.224.2. Surveillance Systems for NCDs
- 10.234.3. Evaluation of NCD Interventions (eg: Lifestyle Modifications, Medication Adherence)
- 10.244.4. Impact of Social Determinants on NCD Trends
- 10.254.5. Global Initiatives to Combat NCDs (WHO Global NCD Action Plan)
- 10.265. Environmental & Occupational Health Risks
- 10.275.1. Principles of Environmental Epidemiology
- 10.285.2. Epidemiologic Methods in Occupational Health
- 10.295.3. Health Impacts of Air and Water Pollution
- 10.305.4. Occupational Exposure to Chemicals and Carcinogens
- 10.315.5. Emerging Issues: Climate Change, Urbanization
- 10.326. Public Health Interventions & Emergency Responses
- 10.336.1. Epidemiologic Basis for Vaccination Programs
- 10.346.2. Tobacco Control: Epidemiology and Policy
- 10.356.3. Managing Infectious Disease Outbreaks
- 10.366.4. Risk Communication During Public Health Emergencies
- 10.376.5. Role of Epidemiology in Disaster Preparedness and Response
- Module 11: Ethical Considerations in Clinical Epidemiology1
1.3 Basic Principles of Epidemiology
1.3.1 Outcome of Disease
Key Concept: What’s the “outcome” of disease?
Example (Practical):
A patient recovering from a heart attack may experience improvements in their clinical outcomes (e.g., heart function) and patient-reported outcomes (e.g., quality of life) but could still face economic outcomes such as hospitalization costs and lost workdays.
Quiz II
Which clinical outcome is most appropriate for tracking effectiveness?
Key Takeaway:
In clinical epidemiology, it’s important to consider how a treatment will work not just in the general population, but also in specific subgroups with different lifestyles and socioeconomic conditions. For this patient, you need to evaluate the availability, cost and contextual factors (e.g., rural healthcare infrastructure) to make a well-informed decision on whether the treatment is feasible and effective for them.
1.3.2 Variables in Research: The Building Blocks of Data
- Independent Variables (IVs): These are the factors or treatments you manipulate or study to see if they cause a change in the dependent variable.
- Dependent Variables (DVs): These are the outcomes you measure to see if they change when the independent variable is applied.
- Confounding Variables : These are external factors that can distort or interfere with the relationship between the independent and dependent variables.
For a variable to be classified as a confounder, it must fulfill three key conditions:
a). Association with the IV: The confounding variable must be related to the independent variable (the factor being manipulated or studied).
Example: If you’re studying the effect of a new anti-hypertension drug on blood pressure, a confounder like age could be related to the drug because older people may be more likely to take the drug, or may need different dosages.
b). Association with the DV: The confounding variable must also have a relationship with the dependent variable (the outcome you’re measuring). This means the confounder influences the outcome, potentially masking or exaggerating the effect of the independent variable on the dependent variable.
Example: In the hypertension drug study, age can affect blood pressure directly (older age is often associated with higher blood pressure), regardless of the drug being tested. This means age is related to the outcome, which is blood pressure.
c). Not an Intermediate Variable (i.e., not in the causal pathway): The confounder must not be an intermediate variable in the causal pathway between the independent and dependent variables. This means that the confounder should not be affected by the independent variable or act as a step between the IV and DV in the cause-effect chain.
Example: In the hypertension study, age is not caused by the drug (IV) nor does it affect how the drug works. However, age directly influences blood pressure, which makes it a confounder.
Example (Practical)
In a clinical trial testing the effect of two different pain management strategies in post-operative patients, the independent variable would be the type of pain management technique used. You could compare Method A (opioid-based pain relief) versus Method B (non-opioid, like acetaminophen or NSAIDs) to determine which method is more effective in managing post-operative pain.
In the same trial, the dependent variable would be the level of pain relief experienced by the patient after receiving either opioid-based pain management (Method A) or non-opioid pain relief (Method B). You could measure this by using a visual analogue scale (VAS) for pain. The goal is to see which method provides better pain control and quicker recovery.
In this pain management study, several confounding variables could influence the outcome, making it hard to determine whether the pain relief is truly due to the pain management method or other factors. For instance:
Age: Older patients may experience different pain levels or recovery times, independent of the pain relief method used.
Comorbidities: Conditions like chronic pain (e.g., osteoarthritis), diabetes, or mental health disorders (e.g., anxiety or depression) could affect the patient's pain perception or response to treatment.
Pre-existing medication use: Patients on regular pain medications or those with a history of opioid use may have different pain thresholds or response to post-operative treatments.
Sociodemographic factors: Patients from different socioeconomic backgrounds may have different access to healthcare or support systems, potentially influencing their recovery.
Quiz III
Key Takeaways:
By identifying and controlling for confounding variables, researchers can ensure their study results are as accurate and reliable as possible.
1.3.3 Population and Sample in Research
Key Concepts:
- Population: The entire group you want to understand or generalize about (e.g., people with diabetes).
- Sample: A subset of the population selected for a study (e.g., 500 people with diabetes in a city).
Example (Practical):
If you are conducting a study on a new vaccine, your population is all individuals at risk of the disease, but you’ll study a sample (a group of patients). How well this sample represents the population impacts the generalizability of the study results.
Activity III
Choose the Best Sampling Method for Antibiotic Resistance Study.
1.3.4 Error in Research: Systematic vs. Random
Key Concepts:
- Systematic Error: Errors that are consistent and predictable, like measurement bias.
- Random Error: Unpredictable and caused by chance, such as human error or environmental factors.
Example (Practical):
In a study measuring blood pressure changes after a new treatment, systematic error could occur if the device used to measure blood pressure is improperly calibrated, while random error could be caused by fluctuations in patient readings due to varying stress levels.
Activity IV
1.3.5 Internal vs. External Validity
Key Concepts:
- Internal Validity: The degree to which the study’s design, execution, and analysis avoid bias, ensuring that the results are accurate for the study group.
- External Validity: The extent to which the study results apply to broader populations or settings.
Example (Practical):
A clinical trial, conducted only on young, healthy volunteers has high internal validity but may have low external validity when applying the results to older or sicker patients.
Activity V
1.3.6 Putting It All Together in Real-Time Practice
Activity VI
Scenario:
Select the true statement A 60-year-old woman with hypertension, diabetes, and a history of stroke presents with a sudden headache. You need to use clinical epidemiology to decide on the next steps for her care.
